Title:
二環式CB2カンナビノイド受容体リガンド
Document Type and Number:
Japanese Patent JP2005523259
Kind Code:
A
Abstract:
The present invention relates to non-classical cannabinoids that are ligands of the peripheral cannabinoid receptor CB2, and to pharmaceutical compositions thereof comprising as an active ingredient novel + alpha-pinene derivatives, which are useful for prevention and treatment of autoimmune diseases including but not limited to rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, myasthenia gravis, diabetes mellitus type I, hepatitis, psoriasis, tissue rejection in organ transplants, malabsorption syndromes such as celiac disease, pulmonary diseases such as asthma and Sjögren's syndrome, inflammation including inflammatory bowel disease, pain including peripheral, visceral, neurophathic inflammatory and referred pain, muscle spasticity, cardiovascular disorders including arrhythmia, hypertension and myocardial ischemia, neurological disorders including stroke, migraine and cluster headaches, neurodegenerative diseases including Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's chorea, prion-associated neurodegeneration, CNS poisoning and certain types of cancer.
More Like This:
| WO/2008/016674 | AGONISTS OF THE SPHINGOSINE- 1- PHOSPHATE RECEPTOR (SLP) |
| JP5735918 | Use of LPA to Promote Pregnancy and Pregnancy Promoters |
| WO/2019/161000 | METHODS FOR TREATING FIBROSIS |
Inventors:
Garzon, Aaron
Fink, George
Menache, Naim
Jakovan, Avihai
Nudelmann, eyelet
Greenberg, orito
Convi Limited
Fink, George
Menache, Naim
Jakovan, Avihai
Nudelmann, eyelet
Greenberg, orito
Convi Limited
Application Number:
JP2003563454A
Publication Date:
August 04, 2005
Filing Date:
January 30, 2003
Export Citation:
Assignee:
Farmos Corporation
International Classes:
A61K31/661; A61K31/045; A61K31/05; A61K31/10; A61K31/12; A61K31/122; A61K31/15; A61K31/255; A61K31/277; A61K31/35; A61K31/6615; A61P1/00; A61P1/16; A61P3/10; A61P9/00; A61P9/06; A61P9/10; A61P9/12; A61P11/00; A61P11/06; A61P17/06; A61P19/02; A61P21/00; A61P21/04; A61P25/00; A61P25/04; A61P25/06; A61P25/14; A61P25/28; A61P29/00; A61P35/00; A61P37/02; A61P43/00; C07C35/31; C07C39/17; C07C39/23; C07C45/29; C07C45/54; C07C45/71; C07C49/443; C07C49/513; C07C49/657; C07C49/747; C07C49/753; C07C69/24; C07C69/30; C07C69/40; C07C69/44; C07C69/60; C07C251/44; C07C255/40; C07F9/09; C07F9/12; (IPC1-7): C07C49/513; A61K31/045; A61K31/05; A61K31/10; A61K31/122; A61K31/15; A61K31/255; A61K31/277; A61K31/661; A61K31/6615; A61P1/00; A61P1/16; A61P3/10; A61P9/00; A61P9/06; A61P9/10; A61P9/12; A61P11/00; A61P11/06; A61P17/06; A61P19/02; A61P21/00; A61P21/04; A61P25/00; A61P25/04; A61P25/06; A61P25/14; A61P25/28; A61P29/00; A61P35/00; A61P37/02; A61P43/00; C07C35/31; C07C39/17; C07C39/23; C07C49/443; C07C49/753; C07C69/24; C07C69/44; C07C69/60; C07C251/44; C07F9/09
Attorney, Agent or Firm:
Hideto Asamura
Hajime Asamura
Naganuma Akio
Yukihiro Ikeda
Hajime Asamura
Naganuma Akio
Yukihiro Ikeda